Modified release preparations containing oxcarbazepine and derivatives thereof
View Patent ↗Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
1. A method of treating seizures, comprising administering to a subject in need thereof a pharmaceutical formulation comprising multiple units, wherein each unit comprises a homogeneous mixture of (a) oxcarbazepine, (b) at least one agent that enhances solubility of oxcarbazepine, and (c) at least one release promoting agent, wherein said release promoting agent comprises a polymer having pH-dependent solubility, and wherein each unit has a release profile for the oxcarbazepine different from other units.
2. The method of claim 1 , wherein said agent that enhances solubility of oxcarbazepine is selected from a group comprising surface active agents, complexing agents, cyclodextrins, pH modifying agents, and hydration promoting agents.
3. The method of claim 2 , wherein the surface active agents are selected from a group comprising sodium docusate, sodium lauryl sulfate, sodium stearyl fumarate, polyethylene oxide (PEO) modified sorbitan monoesters, fatty acid sorbitan esters, and polyethylene oxide-polypropylene oxide-(poly(ethylene oxide)) block copolymers.
4. The method of claim 1 , wherein at least one unit of the pharmaceutical formulation comprises a matrix forming polymer selected from a group comprising swellable polymers and gel-forming polymers.
5. The method of claim 4 , wherein the matrix forming polymer is selected from the group consisting of cellulosic polymers, alginates, gums, cross-linked polyacrylic acids, carageenan; polyvinyl pyrrolidone; polyethylene oxides; and polyvinyl alcohol.
6. The method of claim 1 , wherein the polymer having pH dependent solubility remains intact at pH values of below 4 and dissolves at pH values of more than 4.
7. The method of claim 6 , wherein the polymer having pH dependent solubility dissolves at pH values of more than 5.
8. The method of claim 7 , wherein the polymer having pH dependent solubility dissolves at pH values of more than 6.
9. The method of claim 1 , wherein the polymer having pH dependent solubility comprises cellulose acetate phthalate, cellulose acetate succinate, methylcellulose phthalate, ethylhydroxycellulose phthalate, polyvinylacetate phthalate, polyvinylbutyrate acetate, vinyl acetate-maleic anhydride copolymer, styrene-maleic mono-ester copolymer, or methyl acrylate-methacrylic acid copolymers.
10. The method of claim 1 , wherein the amount of the release promoting agent is from 10% to 90% by weight, and the amount of the solubilizing agent is therefore from 1% to 80% by weight of a dosage form.
11. The method of claim 10 , wherein the pharmaceutical formulation comprises, by weight of the pharmaceutical formulation, 30% to 70% release promoting agent and 1% to 50% solubilizing agent.
12. The method of claim 1 , which exhibits an initial immediate release of oxcarbazepine followed by a modified release of oxcarbazepine.
13. The method of claim 12 , wherein said modified release comprises a delayed release, an extended release, or a combination of delayed and extended release, each release characterized by a different release rate profile.
14. The method of claim 1 , which comprises multiple units having a modified release profile.
15. The method of claim 14 , wherein said modified release profile is selected from a group comprising a delayed release profile, an extended release profile, and a combination of any number of delayed and extended release profiles, each characterized by a different release rate.
16. The method of claim 15 , wherein said units are in the form of minipellets, granules, minitablets and layers.
17. The method of claim 1 , wherein the formulation is administered to the subject once a day.
18. The method of claim 1 , wherein the seizure is an epileptic seizure.
19. The method of claim 1 , wherein the epileptic seizure is a partial seizure or a generalized tonic-clonic seizure.
20. The method of claim 1 , wherein the patient is a child.
21. The method of claim 1 , which exhibits reduced side-effects.
22. A method of treating seizures, comprising administering to a subject in need thereof a pharmaceutical formulation comprising multiple units, wherein each unit comprises a homogeneous mixture of (a) oxcarbazepine, (b) at least one agent that enhances solubility of oxcarbazepine, and (c) at least one release promoting agent, wherein said release promoting agent comprises a polymer having pH-dependent solubility, wherein each unit has a release profile for the oxcarbazepine different from other units, and wherein the amount of oxcarbazepine is effective to produce a steady state blood level of monohydroxy derivative of oxcarbazepine in the range of about 2 μg/ml to about 10 μg/ml.
23. The method of claim 22 , wherein C max levels of monohydroxy derivative of oxcarbazepine (MHD) are in the range of about 6 μg/ml to about 10 μg/ml and C min levels of MHD are in the range of about 2 μg/ml to about 5 μg/ml.
24. The method of claim 22 , wherein the formulation is administered to the subject once a day.
25. A method of treating seizures, comprising administering to a subject in need thereof a pharmaceutical formulation comprising multiple units, wherein each unit consists essentially of a matrix comprising a homogenous mixture of oxcarbazepine, at least one agent that enhances solubility of oxcarbazepine, and at least one release promoting agent, wherein said release promoting agent comprises a polymer having pH-dependent solubility and wherein each unit has a release profile for the oxcarbazepine different from other units.
26. The method of claim 25 , wherein the formulation is administered to the subject once a day.